Literature DB >> 10812285

Naltrexone does not block the subjective effects of oral Delta(9)-tetrahydrocannabinol in humans.

S R Wachtel1, H de Wit.   

Abstract

Delta(9)-tetrahydrocannabinol (THC) and opioids have many common effects. In addition, some THC effects in laboratory animals can be blocked or attenuated by opioid antagonists. This suggests that opioid systems mediate or modulate some THC effects. To determine whether opioid systems mediate THC effects in humans, the effects of the opioid antagonist naltrexone on subjective responses to THC were examined in 14 marijuana users. Subjects participated in a double-blinded, cross-over design in which each subject received all combinations of naltrexone (0 or 50 mg) and THC (0, 7.5, or 15 mg). THC increased heart rate and self-reported drug effects, such as euphoria and marijuana-like effects, and decreased psychomotor performance. Naltrexone increased heart rate and decreased self-reported measures of vigor and hunger but did not alter any of the effects of THC. These results suggest that the subjective, physiological, and behavioral effects of THC in humans are not mediated through opioid systems.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10812285     DOI: 10.1016/s0376-8716(99)00127-1

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  23 in total

Review 1.  State of the art treatments for cannabis dependence.

Authors:  Itai Danovitch; David A Gorelick
Journal:  Psychiatr Clin North Am       Date:  2012-04-10

2.  Open-label pilot study of injectable naltrexone for cannabis dependence.

Authors:  Daniel P Notzon; Meredith A Kelly; C Jean Choi; Martina Pavlicova; Amy L Mahony; Daniel J Brooks; John J Mariani; Frances R Levin
Journal:  Am J Drug Alcohol Abuse       Date:  2018-02-08       Impact factor: 3.829

Review 3.  Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?

Authors:  Patrycja Kleczkowska; Irena Smaga; Małgorzata Filip; Magdalena Bujalska-Zadrozny
Journal:  Neurotox Res       Date:  2016-08-02       Impact factor: 3.911

4.  Effects of daily delta-9-tetrahydrocannabinol treatment on heroin self-administration in rhesus monkeys.

Authors:  David R Maguire; Charles P France
Journal:  Behav Pharmacol       Date:  2016-04       Impact factor: 2.293

5.  Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure.

Authors:  Carl L Hart; Margaret Haney; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin
Journal:  Psychopharmacology (Berl)       Date:  2005-04-14       Impact factor: 4.530

6.  The drug effects questionnaire: psychometric support across three drug types.

Authors:  Meghan E Morean; Harriet de Wit; Andrea C King; Mehmet Sofuoglu; Sandra Y Rueger; Stephanie S O'Malley
Journal:  Psychopharmacology (Berl)       Date:  2012-12-28       Impact factor: 4.530

Review 7.  Self-administration of cannabinoids by experimental animals and human marijuana smokers.

Authors:  Zuzana Justinova; Steven R Goldberg; Stephen J Heishman; Gianluigi Tanda
Journal:  Pharmacol Biochem Behav       Date:  2005-06       Impact factor: 3.533

8.  The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys.

Authors:  Zuzana Justinova; Gianluigi Tanda; Patrik Munzar; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

9.  Interactions between Δ(9)-tetrahydrocannabinol and heroin: self-administration in rhesus monkeys.

Authors:  Jun-Xu Li; Wouter Koek; Charles P France
Journal:  Behav Pharmacol       Date:  2012-12       Impact factor: 2.293

10.  Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception.

Authors:  Jun-Xu Li; Lance R McMahon; Lisa R Gerak; Ginger L Becker; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2008-05-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.